Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
NKGen Biotech, Inc. (NKGN) had Income from Continuous Operations of $-29.41M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-29.12M |
|
-- |
|
-- |
|
$5.10M |
|
$-5.10M |
|
$-24.26M |
|
$-29.36M |
|
$-29.36M |
|
$-29.41M |
|
|
Income from Continuous Operations |
$-29.41M |
$-29.41M |
|
$-29.41M |
|
$-5.10M |
|
$-4.77M |
|
28.83M |
|
28.83M |
|
$-0.85 |
|
$-0.77 |
|
| Balance Sheet Financials | |
$2.46M |
|
$13.30M |
|
$13.77M |
|
$16.23M |
|
$57.97M |
|
$10.84M |
|
$28.17M |
|
$86.14M |
|
$-69.91M |
|
$-69.91M |
|
$-69.91M |
|
44.24M |
|
| Cash Flow Statement Financials | |
$-20.88M |
|
$-0.01M |
|
$20.85M |
|
$0.28M |
|
$0.23M |
|
$-0.04M |
|
$4.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.04 |
|
-- |
|
-- |
|
-0.18 |
|
-0.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-20.89M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
42.08% |
|
42.08% |
|
-181.22% |
|
49.80% |
|
$-1.58 |
|
$-0.72 |
|
$-0.72 |
|